Jump to content

ChrisW

Members
  • Posts

    36
  • Joined

  • Last visited

  • Country

    United States

About ChrisW

  • Birthday 12/25/1951

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

ChrisW's Achievements

  1. Yes, we do FMH screen on all Rh neg mom's who deliver Rh pos infant. What I want to do is discontinue KB's and opt for flow for those that need quantification or for those ED abdominal trauma patients who have not delivered.
  2. I understand the 72 hours. We often have patients in the ED who experienced abdominal trauma and will not be in house for 72 hours. Nor can we guarantee they will follow up with a provider to receive additional doses. In addition, many of our samples are reference samples from remote locations where treatment is being delayed until (currently) the KB results are delivered. I really don't want to continue to offer KBs for times flow can not be accomplished in a timely manner.
  3. We would like to discontinue performing KB stains in our laboratory and perform all fetal bleed determinations using flow cytometry. However, our flow lab is not 24/7. How do others address this issue of turn around time for results?
  4. When we first started using Microplate methods with automation, we saw this also, and had developed a method to deal with and explain discrepancies between tube and automation. Now we seem to be back a square 1 again with discrepancies! YUK!
  5. For those who have switched testing methods from Echo, Neo or Tube to Gel, do you find discrepancies in D antigen typing with Gel vs. historic results from other methods? How are you addressing those?
  6. Thanks for your reply. We looked at our setting and the automatic images synch was inactive so we have switched that to active to see what that does for us. So far Ortho and our IT folks have not been able to get any back ups to write to our network drive. Not sure where the issue lies but am pushing for them to resolve.
  7. For Ortho Vision users - which reports do you save to a back up or archive file? We currently use Immucor Neo for which we perform a weekly archive that saves copies of all the QC results and the testing results to a CD. I'm trying to figure out how our current process compares to what we can do with Vision. Are there requirements to save the automated results if we are entering them into the LIS?
  8. We have been using Cerner Millennium Pathnet since 2005 and our amazing Lab Informatics team has set up QC entry for each test in Pathnet with parameters that we defined. Each test group has an established relationship with a QC group. When opening the result entry worksheet, an appropriate QC group for the tests being resulted must be chosen. If the QC has not been satisfactorily resulted in the established time period, a warning displays and result/interpretation verification can not proceed until QC has been satisfied. This way we are always confident that QC is current for tests being resulted. If computer downtime is expected, we print copies of QC so we know when it has been performed and when it will expire. If unexpected downtime, we perform and record QC as indicated per procedures and enter it into Pathnet during downtime recovery. This process has served us well for the past 12 years and always satisfies AABB, CAP, FDA, and internal auditors.
  9. - Do you administer RhD pos platelets to RhD neg patients? In what situations (always, only when there is a shortage of RhD neg platelets)? To which patient groups do you not recommend RhD incompatible platelets (women < 50 yrs, patients who receive frequent platelet transfusions)? We avoid Rh + platelets to Rh - recipients in pediatric patients and females of child bearing age. If we have to use Rh+ in younger women, our policy is to give RhIg. - Do you have a different policy for apheresis and whole blood derived platelets? We only transfuse apheresis - Do you administer prophylactic Rh immunoglobulin to these patients (everyone, or selected patient groups)? Yes - to women of child bearing age And now for something completely different... - Do you have a policy concerning Kell positive donors and plateletpheresis? Do you defer these donors, or do you have a policy of not actively recruiting these donors for plateletpheresis? We are a transfusion services only so do not collect any donor products.
  10. We are a Level II Trauma Center and dispense uncrossmatched RBCs to the ED multiple times daily. When we deliver the first 2 or 4 units in our Trauma Cooler, the MD or a designee for that MD signs the release form and we return the to Transfusion Services. The Designee is usually the RN that is the recorder for that case. Our form has two spaces - one for name of requesting MD and one for a signature. Our policies describe this process and it has worked well for us for 20 years. The form is signed regardless if the units are transfused or returned to us.
  11. Do you look at the values for the equivocals to determine if you will call it pos or neg or just base it on the observation of the tech looking at the image or well?
  12. We are considering using the edit function on Neo to manually review and interpret equivocal reactions on antibody screen tests performed on Neo. We have been getting many, many equivocals over the past several months and all instrument and reagent solutions are temporary. We are repeating a significant number of tests which is requiring extra resources of reagent and time, not to mention delay to patients. All of the antibody screen repeat test results are negative so we are looking into thoughtfully editing the Neo result. Is anyone routinely using the Edit feature and what is your algorithm for interpretation? Thanks!
  13. Thank you, Malcolm, for being the voice of reason.
  14. We currently have Immucor Neo and are getting proposals form both Immucor and Ortho for our contract renewal. We also are Cerner Millennium so I would be interested in how the Ortho interface process goes for the Vision.
  15. We are trying to move away from CMV seronegative products, except for neonates. Our Pediatric Hematology physicians - about a year and a half ago - stopped ordering seronegative products for their patients following a literature search for current best practices. They found that leukoreduction was at least of equivalent risk of CMV transmission. We are encouraging our adult hematology oncologists to do the same or at least test patients for CMV before ordering.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.